Active substance
Cefalotin
- SFDA 1
- US FDA 11
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| KEFLIN N 2 GM VIAL | 2 g | Powder for injection · Intravenous use | 1 Vial | SAR 24.75 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| KEFLIN | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 4GM BASE/VIAL; EQ 20GM BASE/VIAL | injectable · injection | LILLY | Discontinued | 18 Dec 1974 |
| CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Discontinued | 31 Jan 1984 |
| CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Discontinued | 31 Jan 1984 |
| KEFLIN IN PLASTIC CONTAINER | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | LILLY | Discontinued | 10 Sep 1985 |
| CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Discontinued | 5 Mar 1987 |
| CEPHALOTHIN | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 4GM BASE/VIAL | injectable · injection | INTL MEDICATION | Discontinued | |
| SEFFIN | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued | |
| CEPHALOTHIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 4GM BASE/VIAL | injectable · injection | BRISTOL | Discontinued | |
| CEPHALOTHIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ABBOTT | Discontinued | |
| CEPHALOTHIN SODIUM | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ABBOTT | Discontinued | |
| CEPHALOTHIN SODIUM | EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | ABRAXIS PHARM | Discontinued |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.